IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0110558.html
   My bibliography  Save this article

Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations

Author

Listed:
  • Alice Zwerling
  • Richard G White
  • Anna Vassall
  • Ted Cohen
  • David W Dowdy
  • Rein M G J Houben

Abstract

Introduction: The field of diagnostics for active tuberculosis (TB) is rapidly developing. TB diagnostic modeling can help to inform policy makers and support complicated decisions on diagnostic strategy, with important budgetary implications. Demand for TB diagnostic modeling is likely to increase, and an evaluation of current practice is important. We aimed to systematically review all studies employing mathematical modeling to evaluate cost-effectiveness or epidemiological impact of novel diagnostic strategies for active TB. Methods: Pubmed, personal libraries and reference lists were searched to identify eligible papers. We extracted data on a wide variety of model structure, parameter choices, sensitivity analyses and study conclusions, which were discussed during a meeting of content experts. Results & Discussion: From 5619 records a total of 36 papers were included in the analysis. Sixteen papers included population impact/transmission modeling, 5 were health systems models, and 24 included estimates of cost-effectiveness. Transmission and health systems models included specific structure to explore the importance of the diagnostic pathway (n = 4), key determinants of diagnostic delay (n = 5), operational context (n = 5), and the pre-diagnostic infectious period (n = 1). The majority of models implemented sensitivity analysis, although only 18 studies described multi-way sensitivity analysis of more than 2 parameters simultaneously. Among the models used to make cost-effectiveness estimates, most frequent diagnostic assays studied included Xpert MTB/RIF (n = 7), and alternative nucleic acid amplification tests (NAATs) (n = 4). Most (n = 16) of the cost-effectiveness models compared new assays to an existing baseline and generated an incremental cost-effectiveness ratio (ICER). Conclusion: Although models have addressed a small number of important issues, many decisions regarding implementation of TB diagnostics are being made without the full benefits of insight from mathematical models. Further models are needed that address a wider array of diagnostic and epidemiological settings, that explore the inherent uncertainty of models and that include additional epidemiological data on transmission implications of false-negative diagnosis and the pre-diagnostic period.

Suggested Citation

  • Alice Zwerling & Richard G White & Anna Vassall & Ted Cohen & David W Dowdy & Rein M G J Houben, 2014. "Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-8, October.
    • Handle: RePEc:plo:pone00:0110558
    DOI: 10.1371/journal.pone.0110558
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110558
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0110558&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0110558?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Stephen C Resch & Joshua A Salomon & Megan Murray & Milton C Weinstein, 2006. "Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis," PLOS Medicine, Public Library of Science, vol. 3(7), pages 1-1, July.
    2. David W Dowdy & Maria C Lourenço & Solange C Cavalcante & Valeria Saraceni & Bonnie King & Jonathan E Golub & David Bishai & Betina Durovni & Richard E Chaisson & Susan E Dorman, 2008. "Impact and Cost-Effectiveness of Culture for Diagnosis of Tuberculosis in HIV-Infected Brazilian Adults," PLOS ONE, Public Library of Science, vol. 3(12), pages 1-8, December.
    3. Daniel E Winetsky & Diana M Negoescu & Emilia H DeMarchis & Olga Almukhamedova & Aizhan Dooronbekova & Dilshod Pulatov & Natalia Vezhnina & Douglas K Owens & Jeremy D Goldhaber-Fiebert, 2012. "Screening and Rapid Molecular Diagnosis of Tuberculosis in Prisons in Russia and Eastern Europe: A Cost-Effectiveness Analysis," PLOS Medicine, Public Library of Science, vol. 9(11), pages 1-16, November.
    4. Drummond, Michael F. & Sculpher, Mark J. & Torrance, George W. & O'Brien, Bernie J. & Stoddart, Greg L., 2005. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 3, number 9780198529453.
    5. Hendramoorthy Maheswaran & Pelham Barton, 2012. "Intensive Case Finding and Isoniazid Preventative Therapy in HIV Infected Individuals in Africa: Economic Model and Value of Information Analysis," PLOS ONE, Public Library of Science, vol. 7(1), pages 1-13, January.
    6. David W Dowdy & Karen R Steingart & Madhukar Pai, 2011. "Serological Testing Versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis," PLOS Medicine, Public Library of Science, vol. 8(8), pages 1-10, August.
    7. Judith Legrand & Alexandra Sanchez & Francoise Le Pont & Luiz Camacho & Bernard Larouze, 2008. "Modeling the Impact of Tuberculosis Control Strategies in Highly Endemic Overcrowded Prisons," PLOS ONE, Public Library of Science, vol. 3(5), pages 1-10, May.
    8. Ivor Langley & Basra Doulla & Hsien-Ho Lin & Kerry Millington & Bertie Squire, 2012. "Modelling the impacts of new diagnostic tools for tuberculosis in developing countries to enhance policy decisions," Health Care Management Science, Springer, vol. 15(3), pages 239-253, September.
    9. David W Dowdy & Adithya Cattamanchi & Karen R Steingart & Madhukar Pai, 2011. "Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis," PLOS Medicine, Public Library of Science, vol. 8(7), pages 1-5, July.
    10. Nicolas A Menzies & Ted Cohen & Hsien-Ho Lin & Megan Murray & Joshua A Salomon, 2012. "Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation," PLOS Medicine, Public Library of Science, vol. 9(11), pages 1-17, November.
    11. Anna Vassall & Sanne van Kampen & Hojoon Sohn & Joy S Michael & K R John & Saskia den Boon & J Lucian Davis & Andrew Whitelaw & Mark P Nicol & Maria Tarcela Gler & Anar Khaliqov & Carlos Zamudio & Mar, 2011. "Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis," PLOS Medicine, Public Library of Science, vol. 8(11), pages 1-14, November.
    12. Stephen J Millen & Pieter W Uys & John Hargrove & Paul D van Helden & Brian G Williams, 2008. "The Effect of Diagnostic Delays on the Drop-Out Rate and the Total Delay to Diagnosis of Tuberculosis," PLOS ONE, Public Library of Science, vol. 3(4), pages 1-10, April.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jun Li & Benjamin H K Yip & Chichiu Leung & Wankyo Chung & Kin On Kwok & Emily Y Y Chan & Engkiong Yeoh & Puihong Chung, 2018. "Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-18, January.
    2. Nicola Foster & Lucy Cunnama & Kerrigan McCarthy & Lebogang Ramma & Mariana Siapka & Edina Sinanovic & Gavin Churchyard & Katherine Fielding & Alison D Grant & Susan Cleary, 2021. "Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis," PLOS ONE, Public Library of Science, vol. 16(5), pages 1-21, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. T I Armina Padmasawitri & Gerardus W Frederix & Bachti Alisjahbana & Olaf Klungel & Anke M Hövels, 2018. "Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-20, May.
    2. Tom L. Drake & Angela Devine & Shunmay Yeung & Nicholas P. J. Day & Lisa J. White & Yoel Lubell, 2016. "Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low‐ and Middle‐Income Countries: A Systematic Literature Review," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 124-139, February.
    3. Juliet N Sekandi & Kevin Dobbin & James Oloya & Alphonse Okwera & Christopher C Whalen & Phaedra S Corso, 2015. "Cost-Effectiveness Analysis of Community Active Case Finding and Household Contact Investigation for Tuberculosis Case Detection in Urban Africa," PLOS ONE, Public Library of Science, vol. 10(2), pages 1-18, February.
    4. Anna H van’t Hoog & Frank Cobelens & Anna Vassall & Sanne van Kampen & Susan E Dorman & David Alland & Jerrold Ellner, 2013. "Optimal Triage Test Characteristics to Improve the Cost-Effectiveness of the Xpert MTB/RIF Assay for TB Diagnosis: A Decision Analysis," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-11, December.
    5. Olivia Oxlade & Marcia Pinto & Anete Trajman & Dick Menzies, 2013. "How Methodologic Differences Affect Results of Economic Analyses: A Systematic Review of Interferon Gamma Release Assays for the Diagnosis of LTBI," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-11, March.
    6. Anna Vassall & Lindsay Mangham‐Jefferies & Gabriela B. Gomez & Catherine Pitt & Nicola Foster, 2016. "Incorporating Demand and Supply Constraints into Economic Evaluations in Low‐Income and Middle‐Income Countries," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 95-115, February.
    7. Sze-chuan Suen & Margaret L. Brandeau & Jeremy D. Goldhaber-Fiebert, 2018. "Optimal timing of drug sensitivity testing for patients on first-line tuberculosis treatment," Health Care Management Science, Springer, vol. 21(4), pages 632-646, December.
    8. Simon van der Pol & Paula Rojas Garcia & Maarten J. Postma & Fernando Antoñanzas Villar & Antoinette D. I. Asselt, 2021. "Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review," PharmacoEconomics, Springer, vol. 39(12), pages 1411-1427, December.
    9. Paal Joranger & Arild Nesbakken & Halfdan Sorbye & Geir Hoff & Arne Oshaug & Eline Aas, 2020. "Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 321-334, April.
    10. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    11. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    12. Laurence M. Djatche & Stefan Varga & Robert D. Lieberthal, 2018. "Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events," PharmacoEconomics - Open, Springer, vol. 2(4), pages 371-380, December.
    13. Ties Hoomans & Johan Severens & Nicole Roer & Gepke Delwel, 2012. "Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands," PharmacoEconomics, Springer, vol. 30(3), pages 219-227, March.
    14. Khan, Md. Tajuddin & Kishore, Avinash & Joshi, Pramod Kumar, 2016. "Gender dimensions on farmers’ preferences for direct-seeded rice with drum seeder in India:," IFPRI discussion papers 1550, International Food Policy Research Institute (IFPRI).
    15. Noémi Kreif & Richard Grieve & M. Zia Sadique, 2013. "Statistical Methods For Cost‐Effectiveness Analyses That Use Observational Data: A Critical Appraisal Tool And Review Of Current Practice," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 486-500, April.
    16. Barbara Graaff & Lei Si & Amanda L. Neil & Kwang Chien Yee & Kristy Sanderson & Lyle C. Gurrin & Andrew J. Palmer, 2017. "Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model," PharmacoEconomics - Open, Springer, vol. 1(1), pages 37-51, March.
    17. Christopher Fitzpatrick & Katherine Floyd, 2012. "A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis," PharmacoEconomics, Springer, vol. 30(1), pages 63-80, January.
    18. Hareth Al-Janabi & Terry N. Flynn & Joanna Coast, 2011. "Estimation of a Preference-Based Carer Experience Scale," Medical Decision Making, , vol. 31(3), pages 458-468, May.
    19. Round, Jeff, 2012. "Is a QALY still a QALY at the end of life?," Journal of Health Economics, Elsevier, vol. 31(3), pages 521-527.
    20. Ching-Yun Wei & Ruben G. W. Quek & Guillermo Villa & Shravanthi R. Gandra & Carol A. Forbes & Steve Ryder & Nigel Armstrong & Sohan Deshpande & Steven Duffy & Jos Kleijnen & Peter Lindgren, 2017. "A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies," PharmacoEconomics, Springer, vol. 35(3), pages 297-318, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0110558. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.